Establishment Labs is a global, privately held medical technology company focused on aesthetic technologies and product innovation. Its core offering is the CE-marked Motiva Implants line of ultra-high purity medical-grade silicone breast implants, which are sold in more than 60 countries. The company also markets Divina, a proprietary 3D imaging technology for consultation and surgical planning, and distributes Puregraft, an FDA-cleared and CE-marked fat-purification technology. All of its manufacturing facilities are reported to be compliant with applicable FDA and ISO standards. Management says it will use financing to support R&D into next-generation implants, pursue expanded commercialization in markets where Motiva is approved, and back a proposed FDA trial and entrance into the U.S. market. The company closed a $55 million combined secured credit facility and equity investment to support these initiatives. Establishment Labs is an NYC-based global medical device company focused on breast surgery technologies, designing, developing, manufacturing and marketing advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implants® line is sold in more than 60 countries worldwide. Puregraft® is an FDA-cleared and CE-marked technology that provides plastic surgeons with purified fat for reinjection on the sterile field. The company intends to use the $18M financing to launch Motiva Implants and Puregraft in some of the largest markets worldwide. Over the last six months the company has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil, among others. Establishment Labs is currently scaling up production capacity at its manufacturing plant in Costa Rica. Establishment Labs develops, manufactures and markets the CE-marked Motiva Implants® line and a portfolio of advanced silicone-filled breast and body shaping implants. The Motiva Implants® are manufactured in compliance with ISO and EU requirements and certified under Medical Device Directive 93/42/EEC. Led by CEO Juan José Chacón Quirós, the company is focused on expanding its Motiva Implants® in international markets. Establishment Labs secured up to $15m in debt funding to strengthen its financial position. The company plans to use the funds to finalize a new manufacturing facility and to start United States Food and Drug Administration trials. The financing supports both operational stability and product expansion efforts. Establishment Labs, based in Alajuela, Costa Rica and led by CEO Juan José Chacón-Quirós, designs, develops, manufactures and markets advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implant Matrix® line is produced under ISO and EU requirements and is certified under Medical Device Directive 93/42/EEC. Motiva implants include features such as RFID microtransponders, fully biocompatible nanosurfaces, and TrueTissue™ dynamics and carry an extended product guarantee through Lloyd’s of London. Products are scrutinized by professional Quality Engineers throughout the manufacturing process. Thousands of patients and plastic surgeons in over 50 countries across five continents are using Motiva implants. The company closed a $20M financing round and intends to use the funds to accelerate investment in technology, grow its customer base, and scale the business.

Total raised

$108M

Funding rounds

5

Latest round

Equity

Latest activity

Aug 2017